Filing Details
Theriva Biologics, Inc. (AMEX:TOVX) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 11, 2026.
The Healthcare company reported Q0 revenue of .
10q filedAMEX:TOVX
Theriva Biologics, Inc. (TOVX) Files Quarterly Report for Q0
Theriva Biologics, Inc. (AMEX:TOVX) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 11, 2026.
At publication ·
What changed
Theriva Biologics, Inc. (AMEX:TOVX) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- Theriva Biologics, Inc. (TOVX) filed its quarterly report (Form 10-Q) with the SEC on August 11, 2026, providing unaudited financial statements and management commentary on recent performance.
- The company's stock trades at $0.23 per share with a market capitalization of $7.8 million.
- The 10-Q filing contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last annual filing.
Market Context
Theriva Biologics, Inc.'s stock currently trades at $0.23 with a market capitalization of $7.8M.
The 10-Q provides Theriva Biologics, Inc.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for Theriva Biologics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View TOVX Stock Page
Frequently Asked Questions
Where can I read TOVX's SEC filings?
Browse all filings on our TOVX SEC filings page.
What types of SEC filings does Theriva Biologics, Inc. file?
Public companies like Theriva Biologics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.